Updating results

486 results

Sort: Relevance | Date

Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis (DG36)

Evidence-based recommendations on enzyme-linked immunosorbent assay (ELISA) tests for therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis

Diagnostics guidance Published July 2019

Lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care (DG35)

Evidence-based recommendations on lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care

Diagnostics guidance Published May 2019

Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG34)

Evidence-based recommendations on tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer

Diagnostics guidance Published December 2018

Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: the DYSIS colposcope with DYSISmap and the ZedScan I (DG32)

Evidence-based recommendations on DYSIS colposcope with DYSISmap and ZedScan I for assessing suspected cervical abnormalities in people having colposcopy

Diagnostics guidance Published April 2018

Biomarker tests to help diagnose preterm labour in women with intact membranes (DG33)

Evidence-based recommendations on biomarker tests (Actim Partus, PartoSure, Rapid fFN 10Q Cassette) to diagnose preterm labour in women with intact membranes

Diagnostics guidance Published July 2018

Tests in secondary care to identify people at high risk of ovarian cancer (DG31)

Evidence-based recommendations on tests (IOTA ADNEX, Overa, RMI I, ROMA, IOTA Simple Rules) in secondary care to identify people at high risk of ovarian cancer

Diagnostics guidance Published November 2017

High-throughput non-invasive prenatal testing for fetal RHD genotype (DG25)

Evidence-based recommendations on high-throughput non-invasive prenatal testing (NIPT) for fetal RHD genotype

Diagnostics guidance Published November 2016

Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath (DG12)

Evidence-based recommendations on the NIOX MINO, NIOX VERO and Nobreath devices to measure fractional exhaled nitric oxide concentration in asthma

Diagnostics guidance Published April 2014

SeHCAT (tauroselcholic [75 selenium] acid) for the investigation of diarrhoea due to bile acid malabsorption in people with diarrhoea-predominant irritable bowel syndrome (IBS-D) or Crohn's disease without ileal resection (DG7)

Evidence-based recommendations on SeHCAT (tauroselcholic [75 selenium] acid) for investigating diarrhoea due to bile acid malabsorption (BAM)

Diagnostics guidance Published November 2012

Depth of anaesthesia monitors – Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M (DG6)

Evidence-based recommendations on the Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M depth of anaesthesia monitors

Diagnostics guidance Published November 2012

SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver (DG5)

Evidence-based recommendations on theSonoVue (sulphur hexafluoride microbubbles) contrast agent for contrast-enhanced ultrasound imaging of the liver

Diagnostics guidance Published August 2012

Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system) (DG14)

Evidence-based recommendations on point-of-care coagulometers (the CoaguChek XS system) to self-monitor blood clotting

Diagnostics guidance Published September 2014 Last updated December 2017

Myocardial infarction (acute): Early rule out using high-sensitivity troponin tests (Elecsys Troponin T high-sensitive, ARCHITECT STAT High Sensitive Troponin-I and AccuTnI+3 assays) (DG15)

Evidence-based recommendations on high-sensitivity troponin tests for the early rule-out of acute myocardial infarction (AMI)

Diagnostics guidance Published October 2014

Integrated multiplex PCR tests for identifying gastrointestinal pathogens in people with suspected gastroenteritis (xTAG Gastrointestinal Pathogen Panel, FilmArray GI Panel and Faecal Pathogens B assay) (DG26)

Evidence-based recommendations on integrated multiplex polymerase chain tests for identifying gastrointestinal pathogens in suspected gastroenteritis

Diagnostics guidance Published January 2017

ImmunoCAP ISAC 112 and Microtest for multiplex allergen testing (DG24)

Evidence-based recommendations on ImmunoCAP ISAC 112 and Microtest for multiplex allergen testing to diagnose allergy and predict the risk of allergic reaction

Diagnostics guidance Published May 2016

PlGF-based testing to help diagnose suspected pre-eclampsia (Triage PlGF test, Elecsys immunoassay sFlt-1/PlGF ratio, DELFIA Xpress PlGF 1-2-3 test, and BRAHMS sFlt-1 Kryptor/BRAHMS PlGF plus Kryptor PE ratio) (DG23)

Evidence-based recommendations on PlGF-based testing to help diagnose suspected pre-eclampsia

Diagnostics guidance Published May 2016

Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) (DG22)

Evidence-based recommendations on therapeutic monitoring of TNF-alpha inhibitors in Crohn’s disease

Diagnostics guidance Published February 2016

Integrated sensor-augmented pump therapy systems for managing blood glucose levels in type 1 diabetes (the MiniMed Paradigm Veo system and the Vibe and G4 PLATINUM CGM system) (DG21)

Evidence-based recommendations on the MiniMed Paradigm Veo and Vibe and G4 PLATINUM CGM sensor-augmented pump therapy systems for type 1 diabetes

Diagnostics guidance Published February 2016

Tests for rapidly identifying bloodstream bacteria and fungi (LightCycler SeptiFast Test MGRADE, SepsiTest and IRIDICA BAC BSI assay) (DG20)

Evidence-based recommendations on the LightCycler SeptiFast Test MGRADE, SepsiTest and IRIDICA BAC BSI assay for identifying bloodstream bacteria and fungi

Diagnostics guidance Published February 2016

New generation cardiac CT scanners (Aquilion ONE, Brilliance iCT, Discovery CT750 HD and Somatom Definition Flash) for cardiac imaging in people with suspected or known coronary artery disease in whom imaging is difficult with earlier generation CT scanners (DG3)

Evidence-based recommendations on new generation computed tomography (CT) scanners for cardiac imaging for suspected or known coronary artery disease

Diagnostics guidance Published January 2012 Last updated July 2017

Virtual chromoendoscopy to assess colorectal polyps during colonoscopy (DG28)

Evidence-based recommendations on virtual chromoendoscopy (VCE) using NBI, FICE or i-scan to assess colorectal polyps of 5 mm or less during colonoscopy

Diagnostics guidance Published May 2017

Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27)

Evidence-based recommendations on immunohistochemistry/microsatellite instability testing to guide tests for Lynch syndrome in people with colon cancer

Diagnostics guidance Published February 2017

VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions (DG19)

Evidence-based recommendations on VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions

Diagnostics guidance Published November 2015

Procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay) (DG18)

Evidence-based recommendations on procalcitonin testing for diagnosing and monitoring sepsis (AVIDA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive..

Diagnostics guidance Published October 2015

Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (DG11)

Evidence-based recommendations on faecal calprotectin diagnostic tests for inflammatory diseases of the bowel

Diagnostics guidance Published October 2013

The EOS 2D/3D imaging system (DG1)

Evidence-based recommendations on the EOS 2D/3D imaging system for radiological examinations

Diagnostics guidance Published October 2011

Multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis (DG29)

Evidence-based recommendations on multi frequency bioimpedance devices to guide fluid management for people with chronic kidney disease having dialysis

Diagnostics guidance Published June 2017

Quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care (DG30)

Evidence-based recommendations on quantitative faecal immunochemical tests (OC Sensor, HM-JACKarc and FOB Gold) to guide GP referral for colorectal cancer

Diagnostics guidance Published July 2017

Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) (DG13)

Evidence-based recommendations on viscoelastometric point-of-care testing (ROTEM, TEG and Sonoclot systems) to detect, manage and monitor haemostasis

Diagnostics guidance Published August 2014

Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (DG16)

Evidence-based recommendations on the My5-FU assay for guiding dose adjustment for fluorouracil chemotherapy

Diagnostics guidance Published December 2014

EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (DG9)

Evidence-based recommendations on EGFR-TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (NSCLC)

Diagnostics guidance Published August 2013

Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (DG8)

Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in breast cancer

Diagnostics guidance Published August 2013

Ocrelizumab for treating primary progressive multiple sclerosis (TA585)

Evidence-based recommendations on ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis (MS) in adults

Technology appraisal guidance Published June 2019

Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)

Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for previously untreated multiple myeloma in adults

Technology appraisal guidance Published June 2019

Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586)

Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for multiple myeloma after 1 treatment with bortezomib in adults

Technology appraisal guidance Published June 2019

Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)

Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin), carboplatin and paclitaxel for metastatic non-squamous NSCLC

Technology appraisal guidance Published June 2019

Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)

Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for type 2 diabetes in adults

Technology appraisal guidance Published June 2019

Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal) (TA603)

NICE is unable to make a recommendation about the use in the NHS of lenalidomide (Revlimid) with bortezomib and dexamethasone for untreated multiple myeloma

Technology appraisal guidance Published September 2019

Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA602)

NICE is unable to make a recommendation about the use in the NHS of pomalidomide (Imnovid) with bortezomib and dexamethasone for relapsed or refractory myeloma

Technology appraisal guidance Published September 2019

Bezlotoxumab for preventing recurrent Clostridium difficile infection (terminated appraisal) (TA601)

NICE is unable to make a recommendation about the use in the NHS of bezlotoxumab (Zinplava) for preventing recurrent Clostridium difficile infection in adults

Technology appraisal guidance Published September 2019

Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal) (TA594)

NICE is unable to make a recommendation about the use in the NHS of brentuximab vedotin (Adcetris) for untreated advanced Hodgkin lymphoma in adults

Technology appraisal guidance Published August 2019

Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation (TA578)

Evidence-based recommendations on durvalumab (Imfinzi) for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation

Technology appraisal guidance Published May 2019

Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA579)

Evidence-based recommendations on abemaciclib (Verzenios) for treating hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer

Technology appraisal guidance Published May 2019

Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA581)

Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated advanced renal cell carcinoma in adults

Technology appraisal guidance Published May 2019

Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)

Evidence-based recommendations on enzalutamide (Xtandi) for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults

Technology appraisal guidance Published May 2019

Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) (TA582)

NICE is unable to make a recommendation about the use in the NHS of cabozantinib (Cometriq) for previously treated advanced hepatocellular carcinoma in adults

Technology appraisal guidance Published May 2019

Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) (TA568)

NICE is unable to make a recommendation on abatacept (Orencia) for treating psoriatic arthritis after DMARDs in adults because of no evidence submission from

Technology appraisal guidance Published March 2019

Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (TA567)

Evidence-based recommendations on tisagenlecleucel therapy (Kymriah) for treating relapsed or refractory diffuse large B-cell lymphoma in adults

Technology appraisal guidance Published March 2019

Cochlear implants for children and adults with severe to profound deafness (TA566)

Evidence-based recommendations on cochlear implants for children and adults with severe to profound deafness

Technology appraisal guidance Published March 2019

Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal) (TA564)

NICE is unable to make a recommendation about the use in the NHS of dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive

Technology appraisal guidance Published February 2019